Please login to the form below

Not currently logged in
Email:
Password:

Topas Therapeutics appoints chief development officer and chief medical officer

Rupert Sandbrink joins from Forward Pharma

Topas Therapeutics has appointed Rupert Sandbrink as its new chief development officer and chief medical officer, a role that will see him lead the German group’s development and regulatory affairs.

Forging a 20-year-career spanning clinical development, regulatory and medical affairs and pharmacovigilance business, Dr Sandbrink’s expertise saw him most recently at Forward Pharma, where he served as executive vice president, multiple sclerosis/neurology and immunology.

Prior to that, he held several roles at Bayer, including vice president, head of experimental medicine of women’s health and common mechanism research.

Timm Jessen, chief executive officer, Topas, said: “Rupert has a long and successful track record of bringing drugs and biologics through clinical development and regulatory approval.

“He brings the critical expertise and experience that will help us immensely as we advance and prepare to enter our first program into the clinic. I am very excited to have him join the Topas team.”

At Topas, Dr. Sandbrink will guide projects into the clinic, design and execute clinical development programs and trials and lead the interactions with regulatory authorities.

3rd November 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics